BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ribupatide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ribupatide\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06974851-185@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ribupatide: Phase 3 readout est. (NCT06974851)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: A Phase III Study Evalu
 ating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstru
 ctive Sleep Apnea (OSA) and Obesity\nEstimated primary completion: Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribupatide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069748
 51
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06994650-185@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ribupatide: Phase 3 readout est. (NCT06994650)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: A Multicenter\, Randomi
 zed\, Double-blind\, Placebo-controlled Phase III Clinical Study to Evalua
 te the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructi
 ve Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Venti
 lation (PAP) Therapy\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ribupatide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06994650
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07540754-185@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:ribupatide: Phase 1 readout est. (NCT07540754)
DESCRIPTION:ribupatide\, phase 1\, Obesity.\nStudy: A Study to Evaluate the
  Pharmacokinetics of HRS9531 Injection in Participants With Mild\, Moderat
 e\, and Normal Hepatic Function\nEstimated primary completion: January 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ribupatide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07540754
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07559136-185@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:ribupatide: Phase 1 readout est. (NCT07559136)
DESCRIPTION:ribupatide\, phase 1\, Obesity.\nStudy: A Study to Evaluate the
  Safety\, Tolerability\, Pharmacokinetics and Pharmacodynamics of HRS9531 
 Injection in Adolescents With Obesity\nEstimated primary completion: Febru
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribupatide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0755
 9136
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07060456-185@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:ribupatide: Phase 3 readout est. (NCT07060456)
DESCRIPTION:ribupatide\, phase 3\, Type 2 Diabetes.\nStudy: Efficacy and Sa
 fety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal In
 sulin\nEstimated primary completion: February 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ribupatide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07060456
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285902-185@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:ribupatide: Phase 3 readout est. (NCT07285902)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: A Study Comparing the E
 fficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subj
 ects With Obesity\nEstimated primary completion: March 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ribupatide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07285902
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07458269-185@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:ribupatide: Phase 2 readout est. (NCT07458269)
DESCRIPTION:ribupatide\, phase 2\, Obesity.\nStudy: Efficacy and Safety of 
 Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With
  Obesity Who Do Not Have Diabetes\nEstimated primary completion: May 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ribupatide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07458269
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07599410-185@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:ribupatide: Phase 2 readout est. (NCT07599410)
DESCRIPTION:ribupatide\, phase 2\, Type 2 Diabetes.\nStudy: A Research Stud
 y to Investigate the Efficacy and Safety of HRS9531 Tablets in Participant
 s With Type 2 Diabetes Mellitus\nEstimated primary completion: May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ribupatide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07599410
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670884-185@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:ribupatide: Phase 3 readout est. (NCT07670884)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: A Clinical Study to Eva
 luate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Su
 bjects\nEstimated primary completion: 31 October 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ribupatide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07670884
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284875-185@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:ribupatide: Phase 3 readout est. (NCT07284875)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: Efficacy and Safety of 
 Ribupatide in Participants Living With Obesity or Overweight With Weight-R
 elated Comorbidities Who Do Not Have Diabetes\nEstimated primary completio
 n: February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rib
 upatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07284875
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07793929-185@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280208
DTEND;VALUE=DATE:20280209
SUMMARY:ribupatide: Phase 1 readout est. (NCT07793929)
DESCRIPTION:ribupatide\, phase 1\, Obesity.\nStudy: A Study to Evaluate the
  Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide\nEs
 timated primary completion: 8 February 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ribupatide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07793929
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07660848-185@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:ribupatide: Phase 2 readout est. (NCT07660848)
DESCRIPTION:ribupatide\, phase 2.\nStudy: A Study of HRS-4729 Injection and
  HRS9531 Injection in Participants With Metabolic Dysfunction-Associated S
 teatohepatitis\nEstimated primary completion: March 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/ribupatide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07660848
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284979-185@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:ribupatide: Phase 3 readout est. (NCT07284979)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: Efficacy and Safety of 
 Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo 
 in Participants Living With Obesity Who Do Not Have Diabetes\nEstimated pr
 imary completion: March 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ribupatide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07284979
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284901-185@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280327
DTEND;VALUE=DATE:20280328
SUMMARY:ribupatide: Phase 3 readout est. (NCT07284901)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: Efficacy and Safety of 
 Ribupatide Administered Once Weekly in Participants Living With Obesity or
  Overweight and Diabetes\nEstimated primary completion: 27 March 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ribupatide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07284901
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07709910-185@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:ribupatide: Phase 3 readout est. (NCT07709910)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: A Trial of Ribupatide I
 njection in Participants With Obesity and Knee Osteoarthritis\nEstimated p
 rimary completion: November 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/ribupatide#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07709910
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551492-185@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20310524
DTEND;VALUE=DATE:20310525
SUMMARY:ribupatide: Phase 3 readout est. (NCT07551492)
DESCRIPTION:ribupatide\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 I
 n Participants With Atherosclerotic Cardiovascular Disease\nEstimated prim
 ary completion: 24 May 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ribupatide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07551492
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
